What is myasthenia gravis?Myasthenia gravis is an autoimmune disorder of neuromuscular transmission characterised by fatigable muscle weakness. The disorder is typically mediated by antibodies against the postsynaptic acetylcholine receptor or by antibodies against muscle specific tyrosine kinase. About 10% of patients with myasthenia gravis have a thymoma.1 Any muscle group can be affected in myasthenia gravis, but typically patients present with ocular symptoms, namely diplopia and ptosis. Weakness then becomes generalised in about 80% of patients.2 The most serious complication is myasthenic crisis: acute respiratory failure resulting from myasthenia gravis that requires mechanical ventilation. Myasthenic crisis occurs in about 20% of patients with myasthenia gravis and is a neurological emergency requiring admission to an intensive care unit for respiratory support.3How common is myasthenia gravis? The prevalence of myasthenia gravis in the United Kingdom is estimated at about 15 per 100 000 population, although this figure has increased over time4 5 The incidence is bimodal, with a female:male ratio of 2:1 in younger adults and a reversed sex ratio in older people6 Both the incidence and the prevalence of myasthenia gravis in older patients are greater than previously thought7